B Cell Maturation Antigen Targeted Therapies Market to Witness Decline in Demand By 2017 - 2025

B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor
superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by
TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and
is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for Bcell development and also in autoimmune response. This receptor specially binds to tumor necrosis
factor (TNF) super family member 13b.
BCMA or TNFRSF17 binds to TNF and activates NF-kappaB and MAPK8/JNK. TNFRSF17 also
binds with other TRAF family members and may conduct or transfer signals for cell proliferation
and survival. It is a receptor for TALL-1, and activates NF-kappaB through a NIK-, TRAF5-, IKK-,
and TRAF6- dependent pathway. For TALL-1, TNFRSF17 is identified as NF-kappaB activating
receptor by targets for drug development against certain autoimmune diseases or immunodeficient.
BCMA works as a target of donor B-cell immunity in patients with myeloma who respond to donor
lymphocyte infusions (DLI). BCMA may contribute rejection of tumor in vivo as the response of
antibody to the cell surface. Recent study suggests that BCMA is effective against cells with
multiple myeloma (MM). It is a deadly disease of plasma cells, which needs some mediation by
clinical researchers.
Report Overview and TOC @ https://www.transparencymarketresearch.com/b-cell-maturationantigen-targeted-therapies-market.html
Middle-aged men who have a past history of monoclonal gammopathy have highest risk of
developing multiple myeloma with the exposure of chemicals or radiations. It is important to
increase awareness about effective treatment of cancer and related diseases among the research
community to provide major restraint for increase in BCMA targeted treatment market in future.
Rise in prevalence of multiple myeloma globally is expected to boost the expansion of the BCMA
targeted therapies market in the near future. Multiple myeloma can be fatal and can recur with other
associated serious complications. Prevalence of multiple myeloma and other serious fatal diseases
needs specific diagnosis and targeted treatment at the global level. Therefore, there is an immediate
requirement of effective therapies and medical care, which is likely to fuel the expansion of the
BCMA market in near future.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=25505
The global BCMA targeted therapy market can be segmented into product type, end-user, and
region. In terms of product type, the market can be segmented into CAR-T cells, bispecific
antibodies, and antibody drug conjugates. These are the different kind of products related to B-cell
maturation antigen based on mechanism or function perform with other proteins or cells of body as
identification and destruction of tumor cell lysis of malignant multiple myeloma and conjugate
formation with antibodies. In terms of end-user, the global BCMA targeted therapies market can be
segmented into hospitals and cancer research institutes. In terms of geography, the market can be
segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Key players operating in the BCMA targeted therapies market are Celgene Corporation, Bluebird
Bio, Poseida Therapeutics, Inc., Juno Therapeutics, and Eureka Therapeutics. Several stakeholders
have entered the market for development of novel therapy. They provide funds for research and
development of BMCA targeted therapy in both clinical and commercial research space. Some
clinical stage products that have emerged out of such collaborations include BCMA-CART
(Abramson Cancer Center of the University of Pennsylvania and Novartis) and bb2121 (Celgene
and Bluebird Bio).
Pre Book Full Report @ https://www.transparencymarketresearch.com/b-cell-maturation-antigentargeted-therapies-market.html?secure=NTIxNS41&type=PB
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business
information reports and services. The company’s exclusive blend of quantitative forecasting and
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary data sources and various
tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it
always reflects the latest trends and information. With extensive research and analysis capabilities,
Transparency Market Research employs rigorous primary and secondary research techniques to
develop distinctive data sets and research material for business reports.
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Sales: [email protected]
Website: https://www.transparencymarketresearch.com/
Blog: http://www.tmrblog.com/

Middle-aged men who have a past history of monoclonal gammopathy have highest risk of developing multiple myeloma with the exposure of chemicals or radiations. It is important to increase awareness about effective treatment of cancer and related diseases among the research community to provide major restraint for increase in BCMA targeted treatment market in future. Rise in prevalence of multiple myeloma globally is expected to boost the expansion of the BCMA targeted therapies market in the near future. Multiple myeloma can be fatal and can recur with other associated serious complications.

Download Report